Search

Ekaterina Poliakova-georgan

Examiner (ID: 12423)

Most Active Art Unit
1635
Art Unit(s)
1637, 1635, 1674
Total Applications
898
Issued Applications
492
Pending Applications
151
Abandoned Applications
285

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 18536006 [patent_doc_number] => 20230241093 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-03 [patent_title] => TARGETING ADISPSIN FOR NONALCOHOLIC STEATOHEPATITIS (NASH)- INDUCED LIVER FIBROSIS [patent_app_type] => utility [patent_app_number] => 18/154728 [patent_app_country] => US [patent_app_date] => 2023-01-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9490 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18154728 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/154728
TARGETING ADISPSIN FOR NONALCOHOLIC STEATOHEPATITIS (NASH)- INDUCED LIVER FIBROSIS Jan 12, 2023 Pending
Array ( [id] => 18567418 [patent_doc_number] => 20230257750 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-17 [patent_title] => SIRNA OF ANGPTL3 AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/092202 [patent_app_country] => US [patent_app_date] => 2022-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9835 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -13 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18092202 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/092202
SIRNA OF ANGPTL3 AND USE THEREOF Dec 29, 2022 Pending
Array ( [id] => 18656263 [patent_doc_number] => 20230302157 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => Adeno-Associated Virus Vector Delivery of Muscle Specific Micro-Dystrophin to Treat Muscular Dystrophy [patent_app_type] => utility [patent_app_number] => 18/146840 [patent_app_country] => US [patent_app_date] => 2022-12-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13216 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18146840 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/146840
Adeno-Associated Virus Vector Delivery of Muscle Specific Micro-Dystrophin to Treat Muscular Dystrophy Dec 26, 2022 Pending
Array ( [id] => 18709537 [patent_doc_number] => 20230332156 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => COMPOSITIONS AND METHODS OF TREATING AMYOTROPHIC LATERAL SCLEROSIS (ALS) [patent_app_type] => utility [patent_app_number] => 18/085222 [patent_app_country] => US [patent_app_date] => 2022-12-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 36271 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18085222 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/085222
Compositions and methods of treating amyotrophic lateral sclerosis (ALS) Dec 19, 2022 Issued
Array ( [id] => 18469210 [patent_doc_number] => 20230203494 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => AMPHIREGULIN GENE-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDE AND COMPOSITION FOR PREVENTING AND TREATING FIBROSIS-RELATED DISEASES AND RESPIRATORY DISEASES, COMPRISING SAME [patent_app_type] => utility [patent_app_number] => 18/067363 [patent_app_country] => US [patent_app_date] => 2022-12-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17645 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18067363 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/067363
AMPHIREGULIN GENE-SPECIFIC DOUBLE-STRANDED OLIGONUCLEOTIDE AND COMPOSITION FOR PREVENTING AND TREATING FIBROSIS-RELATED DISEASES AND RESPIRATORY DISEASES, COMPRISING SAME Dec 15, 2022 Abandoned
Array ( [id] => 19051232 [patent_doc_number] => 20240093201 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-03-21 [patent_title] => COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS [patent_app_type] => utility [patent_app_number] => 18/061371 [patent_app_country] => US [patent_app_date] => 2022-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67371 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18061371 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/061371
COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS Dec 1, 2022 Pending
Array ( [id] => 18552426 [patent_doc_number] => 20230250435 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-10 [patent_title] => PCSK9 TARGETING OLIGONUCLEOTIDES FOR TREATING HYPERCHOLESTEROLEMIA AND RELATED CONDITIONS [patent_app_type] => utility [patent_app_number] => 18/060406 [patent_app_country] => US [patent_app_date] => 2022-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22657 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18060406 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/060406
PCSK9 TARGETING OLIGONUCLEOTIDES FOR TREATING HYPERCHOLESTEROLEMIA AND RELATED CONDITIONS Nov 29, 2022 Abandoned
Array ( [id] => 20108490 [patent_doc_number] => 12359199 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-15 [patent_title] => Regulation of gene expression via aptamer-mediated control of self-cleaving ribozymes [patent_app_type] => utility [patent_app_number] => 18/059606 [patent_app_country] => US [patent_app_date] => 2022-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 19 [patent_no_of_words] => 8395 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 130 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18059606 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/059606
Regulation of gene expression via aptamer-mediated control of self-cleaving ribozymes Nov 28, 2022 Issued
Array ( [id] => 19381271 [patent_doc_number] => 20240271141 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => COMPOSITION AND METHOD FOR INHIBITING EXPRESSION OF HEPATITIS B VIRUS (HBV)PROTEIN [patent_app_type] => utility [patent_app_number] => 18/558184 [patent_app_country] => US [patent_app_date] => 2022-11-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38309 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18558184 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/558184
COMPOSITION AND METHOD FOR INHIBITING EXPRESSION OF HEPATITIS B VIRUS (HBV)PROTEIN Nov 28, 2022 Pending
Array ( [id] => 20634607 [patent_doc_number] => 12595477 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-04-07 [patent_title] => Complement Factor B-modulating compositions and methods of use thereof [patent_app_type] => utility [patent_app_number] => 18/058664 [patent_app_country] => US [patent_app_date] => 2022-11-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 41017 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 261 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18058664 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/058664
Complement Factor B-modulating compositions and methods of use thereof Nov 22, 2022 Issued
Array ( [id] => 19930333 [patent_doc_number] => 12303526 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-05-20 [patent_title] => DNA compositions and related methods [patent_app_type] => utility [patent_app_number] => 18/054813 [patent_app_country] => US [patent_app_date] => 2022-11-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 32 [patent_no_of_words] => 26544 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054813 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/054813
DNA compositions and related methods Nov 10, 2022 Issued
Array ( [id] => 18597603 [patent_doc_number] => 20230272400 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => SYNTHESIS METHOD OF TARGETED DRUG nCoVshRNA 2ACE2 [patent_app_type] => utility [patent_app_number] => 18/054508 [patent_app_country] => US [patent_app_date] => 2022-11-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12742 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054508 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/054508
SYNTHESIS METHOD OF TARGETED DRUG nCoVshRNA 2ACE2 Nov 9, 2022 Pending
Array ( [id] => 18692991 [patent_doc_number] => 20230323362 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => COMPLEMENT COMPONENT C1R INHIBITORS FOR TREATING A NEUROLOGICAL DISEASE, AND RELATED COMPOSITIONS, SYSTEMS AND METHODS OF USING SAME [patent_app_type] => utility [patent_app_number] => 18/054113 [patent_app_country] => US [patent_app_date] => 2022-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18349 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18054113 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/054113
COMPLEMENT COMPONENT C1R INHIBITORS FOR TREATING A NEUROLOGICAL DISEASE, AND RELATED COMPOSITIONS, SYSTEMS AND METHODS OF USING SAME Nov 8, 2022 Pending
Array ( [id] => 18771160 [patent_doc_number] => 20230365971 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => METHODS AND COMPOSITIONS FOR MACROPHAGE POLARIZATION [patent_app_type] => utility [patent_app_number] => 18/052785 [patent_app_country] => US [patent_app_date] => 2022-11-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37235 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18052785 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/052785
Methods and compositions for macrophage polarization Nov 3, 2022 Issued
Array ( [id] => 18485250 [patent_doc_number] => 20230212583 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-07-06 [patent_title] => ANTISENSE THERAPEUTICS FOR THE TREATMENT OF CORONAVIRUS [patent_app_type] => utility [patent_app_number] => 18/046235 [patent_app_country] => US [patent_app_date] => 2022-10-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7227 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18046235 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/046235
ANTISENSE THERAPEUTICS FOR THE TREATMENT OF CORONAVIRUS Oct 12, 2022 Pending
Array ( [id] => 20535797 [patent_doc_number] => 12552862 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-02-17 [patent_title] => Oligonucleotides for reduction of PD-L1 expression [patent_app_type] => utility [patent_app_number] => 18/045109 [patent_app_country] => US [patent_app_date] => 2022-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 17 [patent_figures_cnt] => 13 [patent_no_of_words] => 45304 [patent_no_of_claims] => 10 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 85 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18045109 [rel_patent_id] =>[rel_patent_doc_number] =>)
18/045109
Oligonucleotides for reduction of PD-L1 expression Oct 6, 2022 Issued
Array ( [id] => 18240935 [patent_doc_number] => 20230073246 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-09 [patent_title] => BAG3 AS A TARGET FOR THERAPY OF HEART FAILURE [patent_app_type] => utility [patent_app_number] => 17/938209 [patent_app_country] => US [patent_app_date] => 2022-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 25425 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17938209 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/938209
BAG3 AS A TARGET FOR THERAPY OF HEART FAILURE Oct 4, 2022 Pending
Array ( [id] => 19083130 [patent_doc_number] => 20240109931 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/960090 [patent_app_country] => US [patent_app_date] => 2022-10-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 192113 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17960090 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/960090
OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE THEREOF Oct 3, 2022 Abandoned
Array ( [id] => 18389841 [patent_doc_number] => 20230158059 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-05-25 [patent_title] => PREKALLIKREIN-MODULATING COMPOSITIONS AND METHODS OF USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/937344 [patent_app_country] => US [patent_app_date] => 2022-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 37299 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17937344 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/937344
Prekallikrein-modulating compositions and methods of use thereof Sep 29, 2022 Issued
Array ( [id] => 18224928 [patent_doc_number] => 20230063922 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => RIBONUCLEOPROTEINS FOR RNA THERAPEUTICS DELIVERY AND GENE SILENCING [patent_app_type] => utility [patent_app_number] => 17/930088 [patent_app_country] => US [patent_app_date] => 2022-09-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11649 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 182 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17930088 [rel_patent_id] =>[rel_patent_doc_number] =>)
17/930088
RIBONUCLEOPROTEINS FOR RNA THERAPEUTICS DELIVERY AND GENE SILENCING Sep 6, 2022 Pending
Menu